Among these peptides, bombesin and gastrin-releasing peptide (GRP) have been shown to play a physiological and pathophysiological role in pancreatic tissues. Our aim has been to localize bombesin receptors in the human diseased pancreas to identify potential clinical applications of bombesin analogs in this tissue. The presence of bombesin receptor subtypes has been evaluated in specimens of human pancreatic tissues with chronic pancreatitis (n ϭ 23) and ductal pancreatic carcinoma (n ϭ 29) with in vitro receptor autoradiography on tissue sections incubated with 125 ]-bombesin(6 -14) as radioligands and displaced by subtype-selective bombesin receptor agonists and antagonists. GRP receptors were identified in the pancreatic exocrine parenchyma in 17 of 20 cases with chronic pancreatitis. No measurable bombesin receptors were found in the tumor tissue of ductal pancreatic carcinomas, however, GRP receptors were detected in a subset of peritumoral small veins in 19 of 29 samples. Moreover, residual pancreatic islets in these tissues were shown to express the BB3 receptor subtype. These data demonstrate the presence of bombesin receptors in three distinct tissue compartments of the pancreas, namely GRP receptors in the exocrine parenchyma in chronic pancreatitis and in peritumoral vessels around ductal pancreatic carcinomas, and BB3 receptors in residual pancreatic islets. Such a selective expression of bombesin receptor subtypes in pancreatic tissues may not only be of pathophysiological significance but may represent the basis for potential diagnostic and therapeutic clinical applications of bombesin analogs, including GRP receptor scintigraphy to differentiate chronic pancreatitis from ductal pancreatic carcinoma.
]-bombesin(6 -14) as radioligands and displaced by subtype-selective bombesin receptor agonists and antagonists. GRP receptors were identified in the pancreatic exocrine parenchyma in 17 of 20 cases with chronic pancreatitis. No measurable bombesin receptors were found in the tumor tissue of ductal pancreatic carcinomas, however, GRP receptors were detected in a subset of peritumoral small veins in 19 of 29 samples. Moreover, residual pancreatic islets in these tissues were shown to express the BB3 receptor subtype. These data demonstrate the presence of bombesin receptors in three distinct tissue compartments of the pancreas, namely GRP receptors in the exocrine parenchyma in chronic pancreatitis and in peritumoral vessels around ductal pancreatic carcinomas, and BB3 receptors in residual pancreatic islets. Such a selective expression of bombesin receptor subtypes in pancreatic tissues may not only be of pathophysiological significance but may represent the basis for potential diagnostic and therapeutic clinical applications of bombesin analogs, including GRP receptor scintigraphy to differentiate chronic pancreatitis from ductal pancreatic carcinoma. (Lab Invest 2000 , 80:1807 -1817 . N europeptide receptors are overexpressed in different human neoplastic and non-neoplastic diseases: somatostatin receptors in most neuroendocrine tumors (Reubi, 1995b) , vasoactive intestinal peptide receptors in most epithelial tumors (Reubi, 1995a) , gastrin-releasing-peptide (GRP) receptors in all prostatic carcinomas (Markwalder and Reubi, 1999) , and a majority of breast cancers (Gugger and Reubi, 1999) . Substance P receptors can be up-regulated in inflammatory bowel diseases (Mantyh et al, 1991) and rheumatoid arthritis (Walsh et al, 1992) . In addition, they can be overexpressed in peritumoral vessels of various tumor types (Hennig et al, 1995) , an observation made with somatostatin receptors as well (Denzler and Reubi, 1999) . These in vitro results have already led to the development of diagnostic and radiotherapeutic applications, using radiolabeled peptides for in vivo receptor scintigraphy (Behr et al, 1999; Krenning et al, 1995; Virgolini et al, 1994) or peptide radiotherapy (Otte et al, 1998) .
The family of bombesin-like peptides, including the amphibian peptide bombesin as well as the mammalian counterparts GRP and neuromedin B (Erspamer, 1988) , is involved in the regulation of a large number of biological processes in the gut such as exocrine secretion, smooth muscle contraction, and gastrointestinal hormone release. It is of particular interest that these peptides also function as growth factors in several normal and neoplastic tissues, including normal rat pancreas (Lehy and Puccio, 1988) , human small-cell lung cancer, gastrinomas, and in breast, gastric, colorectal, and pancreatic cancer cell lines (Chung et al, 1992; Cuttitta et al, 1985; Frucht et al, 1992; Wang et al, 1996; Yano et al, 1992) . These peptides were shown to participate in autocrine tumor growth stimulation (Cuttitta et al, 1985) . Bombesin-like peptides mediate their action through membranebound receptors (Kroog et al, 1995) . There have been four different bombesin receptor subtypes described: GRP receptors (with high affinity for GRP) (Spindel et al, 1990) , neuromedin B receptors (with high affinity for neuromedin B) (Von Schrenck et al, 1989) (Fathi et al, 1993; Pradhan et al, 1998) , and BB4 receptors (Nagalla et al, 1995) . These receptors belong to the large superfamily of G-protein coupled receptors with seven transmembrane domains.
In mammals, the endogenous GRP ligand has been shown, under normal conditions, to be located primarily in nerves of both the peripheral autonomic and central nervous systems (Dockray et al, 1979; Moghimzadeh et al, 1983) . In the human pancreas, bombesin-like immunoreactivity has been localized by immunohistochemistry to nerve fibers innervating pancreatic acini, capillaries, ducts, and islets (Shimosegawa et al, 1993) . Bombesin receptors have been identified with binding techniques under various experimental conditions in rat, guinea pig, and human pancreas tissues (Hajri et al, 1996; Huang et al, 1990; Jensen et al, 1978; Tang et al, 1997) indicative of a possible functional role of bombesin-like peptides in this organ (Deschodt-Lanckman et al, 1976) . Information on the exact localization and distribution of bombesin receptors and their subtypes in the diseased human pancreas is, however, very limited. The purpose of the present study was to evaluate the localization and distribution of bombesin receptor subtypes in human tissue sections of chronic pancreatitis and pancreatic ductal carcinomas with in vitro receptor autoradiography, using the GRP receptor preferring ligand 125 I-Tyr 4 -bombesin or a universal ligand recognizing all four bombesin receptor subtypes, 125 I-
, Phe 13 , Nle 14 ]-bombesin(6 -14) (Pradhan et al, 1998) .
Results
The primary finding of this study is the expression of bombesin receptor subtypes in the following pancreatic tissues: (a) GRP receptors in the exocrine parenchyma of chronically inflamed pancreas; (b) GRP receptors in the wall of small blood vessels located in the immediate surroundings of ductal pancreatic carcinomas; and (c) BB3 receptors in residual pancreatic islets found in these pancreatic samples. Table 1 summarizes the bombesin receptor data for 23 tissue samples with chronic pancreatitis. Twenty samples contained residual pancreatic parenchyma, three consisted primarily of fibrosis with less than 95% of parenchyma. Seventeen of the twenty parenchymatous samples (85%) expressed bombesin receptors in the residual exocrine parenchyma. Ten of the receptor-positive specimens showed a homogenous distribution of the receptors over the whole exocrine parenchyma, whereas the remaining seven receptorpositive samples showed a more focal distribution of the receptors in the parenchyma. Evidence for the (Coy et al, 1989; Jensen and Coy, 1991) were able, in nanomolar concentrations, to completely inhibit binding of either radioligand. Figure  1 shows one representative example of GRP receptorpositive exocrine parenchyma in chronic pancreatitis with a homogenous, high GRP receptor density. Figure 2 is an example of a focal expression of GRP receptors in the exocrine pancreatic parenchyma of a patient with chronic pancreatitis. Here, the receptors are predominantly expressed at the border of the pancreatic lobules. In three patients, the investigated parenchyma did not show any expression of GRP receptors. One of the patients had only discrete fibrosis and inflammation of the pancreatic tissue, reflect- ing a very mild form of chronic pancreatitis. In general, no correlation was observed between the expression of GRP receptors in the pancreatic parenchyma and the degree of adjacent fibrosis or assessed grade of inflammation in the investigated material (Table 1) . No GRP receptor-positive blood vessels were detected in the specimens with chronic pancreatitis. Figure 3 (6 -14) . An example of such a bombesin receptornegative tumor is shown in Figure 5 . Four of eight ]-bombesin and increasing concentrations of unlabeled bombesin (F), GRP (f), neuromedin B ('), and somatostatin-14 (᭜). Optical density was measured in parenchyma and vessels respectively, using a computer-assisted image processing system. High affinity displacement of the tracer is found with bombesin and GRP whereas neuromedin B shows lower affinity. Somatostatin 14 has no effect. Nonspecific binding was subtracted from all values. The observed rank order of potencies of analogs corresponds to the GRP receptor. Bombesin receptor subtypes in the exocrine parenchyma of chronic pancreatitis (A to F, GRP receptors) and in the residual pancreatic islets of a pancreatic carcinoma sample (G to M, BB3-receptors) using 125 
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tumor samples containing residual exocrine nonneoplastic pancreatic tissue in the resected material showed a weak and focally distributed expression of GRP receptors in the exocrine parenchyma. This tissue displayed histopathological changes consistent with chronic pancreatitis. Interestingly, in 19 of 29 tumor samples, a subset of peritumoral blood vessels also displayed GRP receptors; the labeled vessels were always small veins. A great variability of the GRP receptor incidence in the peritumoral veins was observed among the different samples, ranging from almost no receptors in some vessels to a high density of receptors in others. In several cases, a patchy, nonhomogeneous distribution of the GRP receptors was noticed within individual vessels. These results are also summarized in Table 3 Figure 6 . The first example shows several GRP receptor-positive veins localized around a ductal pancreatic carcinoma. The other example is a high magnification of one peritumoral vein surrounding a ductal pancreatic carcinoma with mucinous components. The GRP receptor positivity in this vein is observed in the smooth muscle. Conversely, vascular GRP receptors could not be identified in the specimens with chronic pancreatitis. Figure 3 shows Table 2 ). These pharmacological characteristics strongly suggest the presence of BB3 receptors in the human pancreatic islets (Pradhan et al, 1998) .
We have attempted to identify bombesin receptors with the same methodology in the healthy human pancreas. In contrast to the human samples with a diseased pancreas or to the normal rat pancreas, all six tested healthy human pancreas tissues were lacking bombesin receptors. It should, however, be noted that (a) the samples containing healthy human pancreas were from donor organs obtained under different conditions than the surgically resected tumor and pancreatitis samples and (b) that the healthy human exocrine pancreas is an enzymatically very active organ that may cause important and rapid degradation of bombesin or of the bombesin receptor. We therefore cannot completely exclude a technical reason for the generation of these negative data, that should, for the time being, be considered with some caution.
Discussion
To our knowledge, this is the first study evaluating bombesin receptor subtypes in cancerous and chronically inflamed human pancreatic tissue using a morphological method, ie, such as receptor autoradiography. Four receptor subtypes of the bombesin-like peptide family are presently known: the neuromedin B receptor with high affinity for neuromedin B, the GRP receptor with high affinity for GRP but lower affinity for neuromedin B, and the bombesin receptor subtypes 3 and 4 with yet unidentified endogenous ligands (Fathi et al, 1993; Nagalla et al, 1995; Spindel et al, 1990; Von Schrenck et al, 1989) . To identify in the present study the various bombesin receptor subtypes involved, we have used two approaches: We used the well established GRP receptor-preferring ligand 125 I- [Tyr 4 ]-bombesin; this ligand could clearly detect GRP receptors in the diseased exocrine parenchyma and peritumoral vessels, characterized by the higher affinity displacement by GRP, bombesin, and GRP receptor antagonists than by neuromedin B. Also, we used ]-bombesin(6 -14) shown to label all four bombesin receptors (Pradhan et al, 1998) . With this ligand we could also detect the GRP receptorexpressing exocrine parenchyma and peritumoral vessels characterized by high affinity displacement by GRP, bombesin, and GRP receptor antagonists but not neuromedin B. In addition, we could identify unequivocally in the residual pancreatic islets a subtype of bombesin receptors previously undetected with 125 I- [Tyr 4 ]-bombesin, which belongs to the BB3 subtype, characterized by high affinity displacement by [D-Tyr 6 , ␤-Ala 11 , Phe 13 , Nle 14 ]-bombesin(6 -14) but not by GRP, bombesin, or neuromedin B (Pradhan et al, 1998) .
A primary finding of the study is the detection of GRP receptors in the exocrine pancreatic parenchyma of most patients with chronic pancreatitis. The density of GRP receptors was variable in the parenchyma and could not be correlated with the degree of fibrosis or inflammation. The presence of GRP receptors in chronic pancreatitis may be functionally meaningful in two aspects: First, their presence is meaningful in relation to the role of bombesin and related peptides as potent mitogens for normal pancreas (Upp et al, 1988) where they stimulate pancreatic growth in suckling and adult animals (Lehy and Puccio, 1988) . During 
ϩ bombesin receptors present, characterized as GRP-R subtype. Ϫ no bombesin receptors. neg, no parenchyma in the sections. NA, not assessable. * Ductal adenocarcinoma with mucinous component.
Fleischmann et al
chronic pancreatitis, the pancreas may try, through these GRP receptors, to make optimal use of the trophic function of GRP to counterbalance the reduction of pancreatic parenchyma occurring in the course of chronic pancreatitis, presumably through regeneration of the lost parenchyma. The particularly prominent GRP receptor expression at the border of the parenchymatous tissue, ie, in close contact with the fibrotically altered lesions, may support such a hypothesis and indicates the likely site of such a counter-regulation. Second, their presence is functionally meaningful in relation to the changes of the intrinsic and extrinsic innervation found in the chronically inflamed pancreas. Indeed, Bockman et al (1988) found ultra-structurally damaged nerves, an increase of the mean diameter of nerves and a decrease of the mean area of tissue served per nerve in chronic pancreatitis versus normal pancreas. Those nerves showed an increased expression of several neuropeptides (Buechler et al, 1992) . Moreover, Shimosegawa et al (1993) discovered in chronic pancreatitis a frequent degeneration and fragmentation of nerve fibers displaying GRP-like immunoreactivity. The intrapancreatic nerve cell bodies, in contrast to those present in the healthy human pancreas, expressed a strong immunoreactivity for GRP, probably as a consequence of disturbed peptide transport, leading to an accumulation of GRP in the perikarya (Shimosegawa et al, 1993) . It is conceivable, therefore, that the GRP receptors in the exocrine parenchyma of chronic pancreatitis will mediate abnormal neuronal information to the remaining exocrine glands, due to an altered GRP-mediated innervation. This abnormal neurotransmission may be one cause for pancreatic pain.
A second important finding of this study relates to ductal pancreatic carcinomas. No bombesin receptors could be found in the tumor tissue of our specimens; however, the GRP receptor subtype of bombesin receptor was detected in peritumoral small veins. The peritumoral vascular receptors in the samples containing ductal pancreatic cancer were identified in the smooth muscles of the veins. As already observed previously for peritumoral vessels expressing somatostatin receptors (Denzler and Reubi, 1999) , not all peritumoral vessels were GRP receptor-positive. The reason for such a focal GRP receptor expression is unknown. Because GRP is known to induce smooth muscle contraction, the presence of GRP receptors in small vessels might affect the regulation of blood flow through vasoconstrictory actions and ultimately influence tumor development. Several mechanisms inducing the expression of GRP receptors in peritumoral vessels may be envisaged. Humoral factors secreted by the tumor (Folkman, 1995) may be instrumental for this enhanced expression. Such putative factors, released into tumoral blood vessels, may reach the peritumoral veins and influence the local vascular neuropeptide receptor expression. Another explanation could relate to the peripheral nervous system and its potential alteration when it innervates the tumoral and the peritumoral region (Mattsson et al, 1979) . A neurogenic reaction has indeed been postulated to occur as a general biological response to various types of damage (Levine et al, 1986) , including that caused by neoplasms; it may involve the peripheral peptidergic nervous system and its peptide receptors, including GRP, because it has been shown that GRPcontaining nerves occasionally reach the vasculature (De Giorgio et al, 1993) .
The third important finding of this study is the identification, for the first time, of bombesin receptors of the BB3 subtype in human pancreatic islets. Because very little is known presently about the BB3 receptors (Fathi et al, 1993; Pradhan et al, 1998) , the observation of a high density of this receptor in pancreatic islets, and moreover in the human species, may considerably increase the interest for this BB3 receptor subtype. It provides a possibility to further investigate its characteristics in a well defined human organ. This may open new avenues regarding the biology of this endocrine organ, and, as consequence, for future development and clinical applications of BB3-selective drugs.
A potential clinical application of the present findings may be the therapeutic and diagnostic use of GRP analogues. For pancreatic cancer, the modulation of hemodynamic parameters with GRP analogues in the immediate tumor surroundings might be a potential strategy to influence tumor growth through a putative lack of nutrients and oxygen. In chronic pancreatitis, it would be of diagnostic value to visualize chronic inflammatory pancreatic processes and to be able to differentiate them from neoplastic changes by means of GRP receptor scintigraphy in vivo (Behr et al, 1999; Krenning et al, 1995) . It may be worth evaluating the use of GRP receptor antagonists (Jensen and Coy, 1991) for pain treatment in this disease to determine whether the parenchymatous GRP receptors may be responsible in part for the massive pain symptoms encountered during chronic pancreatitis. Alternatively, one may think of relieving pain in chronic pancreatitis with the use of radiolabeled GRP by locally destroying the altered nerves and reducing pain. This principle of selective destruction of receptor expressing tissues with radiotherapy is presently applied for somatostatin receptor expressing neuroendocrine and brain tumors (Merlo et al, 1999; Otte et al, 1998) . Although largely speculative, these suggestions for pain therapy of chronic pancreatitis may represent an alternative to surgery in cases of persistent pain necessitating pancreatectomy.
Material and Methods

Patients
Tissues were obtained from 23 patients with chronic pancreatitis and 29 patients with pancreatic ductal carcinomas at the Department of Visceral Surgery, University Hospital (Berne, Switzerland). The samples (one per patient; 1-2 cm in diameter) of pathologic pancreatic tissue were collected in the operating room and immediately frozen at Ϫ80°C. Most of these tissue samples were investigated for other peptide receptors in previous experiments (Reubi et al, 1998) and their diagnoses were all reviewed by a pathologist (Oertel et al, 1994) . All tested cases are listed in Tables  1 to 3 .
Bombesin Receptor Autoradiography
Twenty-micron thick cryostat sections of the tissue samples were processed for receptor autoradiography as described in detail previously for other peptide receptors (Reubi et al, 1990) . The radioligand used was 125 I- [Tyr 4 ]-bombesin, known to preferentially label GRP receptors (Vigna et al, 1987) . For autoradiography, tissue sections were mounted on precleaned microscope slides and stored at Ϫ20°C for at least 3 days to improve adhesion of tissue to the slide. The sections were then processed as described previously (Markwalder and Reubi, 1999;  Fleischmann et al Vigna et al, 1987) . They were first preincubated in 10 mM N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES), pH 7.4, for 5 minutes at room temperature. They were then incubated in 10 mM HEPES, 130 mM NaCl, 4.7 mM KCl, 5 mM MgCl 2 , 1 mM ethylenglycol-bis (␤-aminoethylether)-N-N'-tetraacetic acid, 0.1% bovine serum albumin, 100 g/ml bacitracin (pH 7.4), and approximately 100 pM 
